F8 and hemophilia: The peaks generated with replacement therapies are titratable and usually reach levels within the normal range of coagulation activation, while the flat steady state curve achieved with emicizumab, a bispecific antibody mimicking the action of FVIII, generally corresponds to an unmodifiable coagulation activation similar to that displayed by people with mild haemophilia with no ability to correct FVIII equivalent activity in the normal range.